Drug profile · INN
pramlintide acetate
SYMLIN
pramlintide acetate (SYMLIN) is a amylin receptor amy3; calcr/ramp3 agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — pramlintide acetate
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
pramlintide acetate (SYMLIN) is a amylin receptor amy3; calcr/ramp3 agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Amylin receptor AMY3; CALCR/RAMP3 agonist
Primary target: Amylin receptor AMY1, CALCR/RAMP1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Frequently asked questions
What is pramlintide acetate?
pramlintide acetate (SYMLIN) is a amylin receptor amy3; calcr/ramp3 agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for pramlintide acetate?
SYMLIN is a marketed brand name for pramlintide acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pramlintide acetate?
pramlintide acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.